<DOC>
	<DOCNO>NCT00257465</DOCNO>
	<brief_summary>The purpose study determine whether vaccine compose patient ' melanoma cell treat chemical , dinitrophenyl ( DNP ) ( call hapten ) , safe stimulates immune response patient ' cancer cell .</brief_summary>
	<brief_title>Trial Autologous , Hapten-Modified Vaccine Patients With Stage III IV Melanoma</brief_title>
	<detailed_description>Patients stage III IV melanoma need least one tumor mass least 2.5 cm ( 1 inch ) diameter remove vaccine production . If vaccine successfully make patient eligible , patient assign receive one 4 dos vaccine , include one group receive zero dose . All patient receive injection vaccine part immune system test receive low dose cyclophosphamide BCG . Eight injection vaccine administer injection skin arm 6 month period . Before vaccine administration , patient test immunity melanoma cell DTH testing , similar tuberculosis test . All side effect cause vaccine record .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>stage III IV melanoma least one tumor mass least 2.5 cm diameter excise make vaccine good performance status brain metastasis need steroid immunosuppressive drug positive PPD test positive test HIV , hepatitis B ( antigen ) , hepatitis C serious medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>autologous</keyword>
</DOC>